LAKEWOOD, Colo.--(BUSINESS WIRE)--Terumo BCT announced today that the Spectra Optia system mononuclear cell (MNC) collection protocol is now cleared by the U.S. Food and Drug Administration (FDA) and available for use in the United States. The availability of the MNC collection protocol—in addition to the therapeutic plasma exchange (TPE) protocol—on the Spectra Optia system, brings the value of efficiency, purity and consistency to cell collections—benefitting patients, clinicians and laboratory processes.
